FindTrial
Sign In

Cohort study of allogeneic hematopoietic stem cell transplantation combined with mesenchymal stem cell infusion in the treatment of thalassemia

Cohort study of allogeneic hematopoietic stem cell transplantation combined with mesenchymal stem cell infusion in the treatment of thalassemia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400089562
Enrollment
Unknown
Registered
2024-09-11
Start date
2024-09-15
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thalassemia major

Interventions

Hematopoietic Stem Cell Transplantation with MSC infusion:None
Hematopoietic Stem Cell Transplantation only:None

Sponsors

The Second Affiliated Hospital of Army Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Hemoglobin electrophoresis/Gene Diagnostics DiagnosTM, transfusion dependent; 2. Receive full and half congruent HLA-derived hematopoietic stem cell transplantation; 3. Age 1-60 years old, gender is not limited; 4. No serious organ damage; 5. Available for follow-up

Exclusion criteria

Exclusion criteria: 1. Serious dysfunction of major organs; 2. Tumors and serious infectious diseases; 3. Severe active infection

Design outcomes

Primary

MeasureTime frame
Cumulative incidence of cGvHD;—

Secondary

MeasureTime frame
time to platelet engraftment;time to neutrophil engraftment;—

Countries

China

Contacts

Public ContactXi Zhang

The Second Affiliated Hospital of Army Military Medical University

zhangxxi@sina.com+86 23 6876 3198

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026